These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 31167663)

  • 21. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
    Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
    Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study.
    Dixon DL; Billingsley HE; Canada JM; Trankle CR; Kadariya D; Cooke R; Hart L; Van Tassell B; Abbate A; Carbone S
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):407-410. PubMed ID: 34132690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?
    Martín E; Castillo JC; González-Manzanares R; López Aguilera J; Perea J; Anguita M
    Cardiol J; 2022; 29(1):166-169. PubMed ID: 34931694
    [No Abstract]   [Full Text] [Related]  

  • 24. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
    Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
    J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
    Tanaka A; Imai T; Shimabukuro M; Nakamura I; Matsunaga K; Ozaki Y; Minamino T; Sata M; Node K;
    J Diabetes Investig; 2022 Dec; 13(12):1990-1999. PubMed ID: 36114704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.
    Skelley JW; Carter BS; Roberts MZ
    Vasc Health Risk Manag; 2018; 14():419-428. PubMed ID: 30573964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
    Kario K; Hoshide S; Okawara Y; Tomitani N; Yamauchi K; Ohbayashi H; Itabashi N; Matsumoto Y; Kanegae H
    J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1527-1535. PubMed ID: 30246286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
    Vaduganathan M; Sattar N; Xu J; Butler J; Mahaffey KW; Neal B; Shaw W; Rosenthal N; Pfeifer M; Hansen MK; Januzzi JL
    J Am Coll Cardiol; 2022 Feb; 79(5):432-444. PubMed ID: 35115099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
    Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
    J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
    Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL
    Diabetologia; 2021 Oct; 64(10):2147-2158. PubMed ID: 34415356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
    Sarraju A; Li J; Cannon CP; Chang TI; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW
    Am Heart J; 2021 Mar; 233():141-148. PubMed ID: 33358942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: A systematic review and meta-analysis.
    Khan MS; Usman MS; Siddiqi TJ; Memon MM; Shah SJ; Khan SS
    Eur J Prev Cardiol; 2019 Oct; 26(15):1680-1682. PubMed ID: 30755019
    [No Abstract]   [Full Text] [Related]  

  • 40. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.